Vectura Group plc Annual Report and Accounts 2017
1 2 Vectura Group plc Annual Report and Accounts 2017
Device Formulation Development 3 Annual Report and Accounts 2017 Vectura Group plc
Vectura Group plc Annual Report and Accounts 2017
Operational highlights 5 Annual Report and Accounts 2017 Vectura Group plc
6 Vectura Group plc Annual Report and Accounts 2017
services  7 Annual Report and Accounts 2017 Vectura Group plc
for future growth 9 Annual Report and Accounts 2017 Vectura Group plc
12 Vectura Group plc Annual Report and Accounts 2017
3.5% CAGR 2015–25 14 Vectura Group plc Annual Report and Accounts 2017
share of global medicine spend increasing from 15 Annual Report and Accounts 2017 Vectura Group plc
IN-MARKET PRODUCTS 18 Vectura Group plc Annual Report and Accounts 2017
18 Vectura Group plc Annual Report and Accounts 2017
capabilities 20 Vectura Group plc Annual Report and Accounts 2017
® 21 Annual Report and Accounts 2017 Vectura Group plc
Vectura Group plc Annual Report and Accounts 2017
inhalation technique 24 Vectura Group plc Annual Report and Accounts 2017
Device AND formulation 29 Annual Report and Accounts 2017 Vectura Group plc
licensing arrangements and future pipeline 30 Vectura Group plc Annual Report and Accounts 2017
32 Vectura Group plc Annual Report and Accounts 2017
34 Vectura Group plc Annual Report and Accounts 2017
In-market products – Inhaled continued 37 Annual Report and Accounts 2017 Vectura Group plc
37 Annual Report and Accounts 2017 Vectura Group plc Generic programmes 
40 Vectura Group plc Annual Report and Accounts 2017
42 Vectura Group plc Annual Report and Accounts 2017 A patient’s breathing pattern can alter the efficiency of drug delivery 
Analyst indicative sales range 45 Annual Report and Accounts 2017 Vectura Group plc
optimum inhalation technique 46 Vectura Group plc Annual Report and Accounts 2017
(£6.6m) 47 Annual Report and Accounts 2017 Vectura Group plc
48 Vectura Group plc Annual Report and Accounts 2017
to a number of risks and uncertainties 49 Annual Report and Accounts 2017 Vectura Group plc
Review of high risks Risk registers 50 Vectura Group plc Annual Report and Accounts 2017
Revenue £148.0m (£16.6m) £131.4m £126.3m 4.0% 58 Vectura Group plc Annual Report and Accounts 2017
60 Vectura Group plc Annual Report and Accounts 2017
FINANCIAL REVIEW CONTINUED 63 Annual Report and Accounts 2017 Vectura Group plc
Our values: 66 Vectura Group plc Annual Report and Accounts 2017
68 Vectura Group plc Annual Report and Accounts 2017
A R 74 Vectura Group plc Annual Report and Accounts 2017
Development 75 Annual Report and Accounts 2017 Vectura Group plc
Operations 76 Vectura Group plc Annual Report and Accounts 2017
78 Vectura Group plc Annual Report and Accounts 2017
82 Vectura Group plc Annual Report and Accounts 2017
86 Vectura Group plc Annual Report and Accounts 2017
88 Vectura Group plc Annual Report and Accounts 2017
90 Vectura Group plc Annual Report and Accounts 2017
92 Vectura Group plc Annual Report and Accounts 2017
94 Vectura Group plc Annual Report and Accounts 2017
96 Vectura Group plc Annual Report and Accounts 2017
Total 60% 54–56% 97 Annual Report and Accounts 2017 Vectura Group plc
100 Vectura Group plc Annual Report and Accounts 2017
Vectura Group plc also operates a Sharesave (SAYE) Share Option Scheme for employees and Executive Directors.
102 Vectura Group plc Annual Report and Accounts 2017
The following graph shows Vectura Group plc’s cumulative total shareholder return (TSR) over the last nine financial years relative to 
104 Vectura Group plc Annual Report and Accounts 2017
106 Vectura Group plc Annual Report and Accounts 2017
108 Vectura Group plc Annual Report and Accounts 2017
110 Vectura Group plc Annual Report and Accounts 2017 2.
112 Vectura Group plc Annual Report and Accounts 2017 2.
114 Vectura Group plc Annual Report and Accounts 2017 4.
116 Vectura Group plc Annual Report and Accounts 2017 CONSOLIDATED INCOME STATEMENT
120 Vectura Group plc Annual Report and Accounts 2017 CONSOLIDATED CASH FLOW STATEMENT
*  Following an FRC corporate reporting review of the Group’s 2016 Annual Report and Accounts, in accordance with IAS 7 paragraph 16, exceptional merger transaction costs disclosed as cash 
The financial statements of the parent company, Vectura Group plc (UK company number 03418970), have been prepared in accordance with 
122 Vectura Group plc Annual Report and Accounts 2017 1.
124 Vectura Group plc Annual Report and Accounts 2017 2.
The Group is managed on the basis of a single reportable segment, being the development and supply of pharmaceutical products.
126 Vectura Group plc Annual Report and Accounts 2017 2.
128 Vectura Group plc Annual Report and Accounts 2017 3.
The Group is managed on the basis of a single reportable segment, being the development and supply of pharmaceutical products, and as 
130 Vectura Group plc Annual Report and Accounts 2017 9.
132 Vectura Group plc Annual Report and Accounts 2017 13.
134 Vectura Group plc Annual Report and Accounts 2017 15.
136 Vectura Group plc Annual Report and Accounts 2017 16.
138 Vectura Group plc Annual Report and Accounts 2017 18.
Non-current financial assets principally include £5.8m (2016: nil) of amounts receivable from a development partner for manufacturing 
140 Vectura Group plc Annual Report and Accounts 2017 24.
142 Vectura Group plc Annual Report and Accounts 2017 24.
1 44 Vectura Group plc Annual Report and Accounts 2017 26.
146 Vectura Group plc Annual Report and Accounts 2017 28.
The Group operates various share-based compensation plans and further information is provided in the Remuneration report.
The remuneration of the Directors, who are the key management personnel of the Group, was £2.6m and is set out below:
150 Vectura Group plc Annual Report and Accounts 2017 COMPANY BALANCE SHEET
The Company financial statements of Vectura Group plc were approved and authorised for issue by the Board of Directors on 20 March 2018 
152 Vectura Group plc Annual Report and Accounts 2017 NOTES TO THE COMPANY FINANCIAL STATEMENTS
On 14 November 2017 Vectura Group plc announced that the Board has approved a share buyback to return up to £15.0m of capital 